| Name | Title | Contact Details |
|---|
Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians and scientists in New York City and around the world. The doctors and scientists of Weill Cornell Medicine — faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization—are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Side`s scientific corridor, Weill Cornell Medicine`s powerful network of collaborators extends to its parent university Cornell University; to Qatar, where Weill Cornell Medicine-Qatar offers a Cornell University medical degree; and to programs in Tanzania, Haiti, Brazil, Austria, and Turkey. Weill Cornell Medicine faculty provide comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Lower Manhattan Hospital, and NewYork-Presbyterian Queens. Weill Cornell Medicine is also affiliated with Houston Methodist. At Weill Cornell Medicine, we connect the collective power of our integrated partners in education and research to provide world-class care for our individual patients—#CareDiscoverTeach.
We are a team of certified professionals who have turned fitness and wellness into a concierge service for busy people who want to look and feel good...but don’t think they have the time for it. You always hear that wellness is a “life-long journey”...
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
Community Health Choice is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NeoLife is a pioneer in whole food nutrition supplementation since 1958, with a commitment to end the trend of poor wellness and poverty.